XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Slow-growing and non-dividing bacteria exhibit tolerance to many antibiotics. However, membrane-active agents may act against bacteria in all growth phases. We sought to examine whether the novel porphyrin antibacterial agents XF-70 and XF-73, which have rapid membrane-perturbing activity against Staphylococcus aureus, retained antistaphylococcal activity against growth-attenuated cells. METHODS: The killing kinetics of XF-70, XF-73 and various comparator agents against exponential phase cultures of S. aureus SH1000 were compared with effects on cells held at 4 degrees C, non-growing cultures expressing the stringent response induced by mupirocin and bacteria in the stationary phase. Biofilms of S. aureus SH1000 were generated with the Calgary device to examine the activities of XF-70 and XF-73 under a further system exhibiting diminished bacterial growth. RESULTS: Cold culture, stringent response and stationary phase cultures remained susceptible to XF-70 and XF-73, which caused > or =5 log reductions in viability over 2 h. During this period the most active comparator agents (chlorhexidine and cetyltrimethylammonium bromide) only promoted a 3 log drop in viability. XF-70 and XF-73 were also highly active against biofilms, with both agents exhibiting low biofilm MICs (1 mg/L) and minimum biofilm eradication concentrations (2 mg/L). CONCLUSIONS: XF-70 and XF-73 remained highly active against various forms of slow-growing or non-dividing S. aureus. The results support the hypothesis that membrane-active agents may be particularly effective in eradicating slow- or non-growing bacteria and suggest that XF-70 and XF-73 could be utilized to treat staphylococcal infections where the organisms are only dividing slowly, such as biofilm-associated infections of prosthetic devices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of biofilm resistance to antimicrobial agents
Mah, T.-F. C., & O'Toole, G. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01913-2 · Cited by 3,921
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Cited by
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Self-citationAntibiotic resistance and persistence—implications for human health and treatment perspectives
Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020) · The EMBO Reports · doi:10.15252/embr.202051034 · Cited by 850
“Various other membrane-active small molecules like NT-61, a fluoroquinolone (Hu et al , 2010), XF-73 (Ooi et al , 2010) or NCK10 (Ghosh et al , 2015) have shown activity against S. aureus persisters (Fig 5B).”
Bacterial Biofilm Eradication Agents: A Current Review
Verderosa, A. D., Totsika, M., & Fairfull-Smith, K. E. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00824 · Cited by 555
Mofazzal Jahromi, M. A., Sahandi Zangabad, P., Moosavi Basri, S. M., Sahandi Zangabad, K., Ghamarypour, A., Aref, A. R., Karimi, M., & Hamblin, M. R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.001 · Cited by 551
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Metadata
- Authors
- Ooi, N., Miller, K., Randall, C., Rhys-Williams, W., Love, W., & Chopra, I.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-04
- Volume
- 65
- Issue
- 1
- Pages
- 72-78
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2110554420
- Cited by
- 94
- References
- 2
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.